Summary

Report Overview
Middle East and Africa Diabetes Devices Market reached US$ 1.44 billion in 2023 and is expected to reach US$ 2.77 billion by 2031, growing at a CAGR of 8.7% during the forecast period 2024-2031.
Diabetes is a group of metabolic disorders characterized by a chronically high blood sugar level. Common symptoms include frequent urination, increased thirst, and increased hunger. Diabetes, if untreated, may cause an array of health problems.
Acute consequences include diabetic ketoacidosis, hyperosmolar hyperglycemia, and death. Long-term risks include cardiovascular illness, stroke, chronic kidney disease, foot ulcers, nerve damage, eye damage, and cognitive impairment. Diabetes devices are used to monitor and manage the disease symptoms and are useful for estimating the onset of the adverse effects of the disease.
Market Dynamics: Drivers & Restraints
Growing awareness among individuals
The growing awareness of disease care is driving the Middle East and Africa market. With the rising prevalence of chronic diseases, there is a rise in demand, resulting in market expansion.
Diabetes management courses and campaigns will help improve health literacy by allowing users to comprehend different tests and equipment. As a result, improving health literacy will assist developing markets such as MEA in positioning themselves for success in the diabetes care devices market.
With the growing prevalence of diabetes in the regions, there is a growing demand for diabetes devices to manage and measure glucose levels which is crucial for treating diabetes. The World Health Organization stated that more than half (54%) of people living with diabetes in the African region are undiagnosed.
Initiating awareness among the individuals in the region by governments could help in increasing the demand for diabetes devices. For instance, Saudi schools, hospitals, and universities are marking World Diabetes Day on November 14 with education campaigns on the disease’s health risks and its potential to kill.
High costs associated with diabetes devices
Diabetic devices such as continuous glucose monitors (CGMs) and insulin pumps, are costly and cannot be afforded by many individuals. For individuals, particularly those without insurance or in areas with limited resources for healthcare, high expenses can be challenging. Thus, the high costs of these devices could hamper the market growth.
Market Segment Analysis
The Middle East and Africa diabetes devices market is segmented based on device type, and distribution channel.
Blood glucose monitoring (BGM) devices segment is expected to dominate the market share
Blood glucose monitoring (BGM) devices hold a major portion of the market share and are expected to continue throughout the forecast period. This is due to the increasing technological advancements in the devices and the increasing number of launches of the devices. The increasing patient pool of diabetes in the region also plays a dominant role in holding the segment in a significant position in the market share.
Medical device manufacturing companies are introducing advanced devices that are accurate and efficient. For instance, GulfDrug LLC (Gulf Drug) of the United Arab Emirates (UAE) officially announced the launch of its tubeless, wearable, and disposable insulin pump “EOPatch” in the UAE. It becomes possible in the UAE to control and manage insulin infusions with EOPatch directly from Android and iOS smartphones using the brand-new Narsha app.
Additionally, on Aug. 17, 2023, Nemaura Medical, Inc. received SFDA (Saudi Food and Drug Authority) approval for sugarBEAT, its non-invasive wearable glucose sensor.
Market Segmentation
By Device Type
Blood Glucose Monitoring (BGM) Devices
Self-Monitoring Devices
Blood Glucose Meters
Testing Strips
Lancets
Continuous Glucose Monitoring Devices
Sensors
Durables
Others
Insulin Delivery Devices
Insulin Pumps
Insulin Pens
Insulin Syringes
Jet Injectors
Others
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Diabetes Clinics/Centers
Online Pharmacies
Others
Market Competitive Landscape
The major players in the market include Hoffmann-La Roche AG, Medtronic Plc, Abbott Laboratories, Novo Nordisk A/S, DexCom, Inc., Nipro Medical, Sol-Millennium Medical Group, SABIC, Colexa Biosensor Ltd. and AMETEK.Inc. among others.
Why Purchase the Report?
To visualize the Middle East and Africa diabetes devices market segmentation based on device type, and distribution channel, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of diabetes devices market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.
The Middle East and Africa diabetes devices market report would provide approximately 53 tables, 47 figures, and 176 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Device Type
3.2. Snippet by Distribution Channel
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing awareness among individuals
4.1.2. Restraints
4.1.2.1. High costs associated with diabetes devices
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By Device Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
6.1.2. Market Attractiveness Index, By Device Type
6.2. Blood Glucose Monitoring (BGM) Devices*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Self-Monitoring Devices
6.2.3.1. Blood Glucose Meters
6.2.3.2. Testing Strips
6.2.3.3. Lancets
6.2.4. Continuous Glucose Monitoring Devices
6.2.4.1. Sensors
6.2.4.2. Durables
6.2.4.3. Others
6.3. Insulin Delivery Devices
6.3.1. Insulin Pumps
6.3.2. Insulin Pens
6.3.3. Insulin Syringes
6.3.4. Jet Injectors
6.3.5. Others
6.4. Others
7. By Distribution Channel
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
7.1.2. Market Attractiveness Index, By Distribution Channel
7.2. Hospital Pharmacies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Retail Pharmacies
7.4. Diabetes Clinics/Centers
7.5. Online Pharmacies
7.6. Others
8. Competitive Landscape
8.1. Competitive Scenario
8.2. Market Positioning/Share Analysis
8.3. Mergers and Acquisitions Analysis
9. Company Profiles
9.1. Hoffmann-La Roche AG*
9.1.1. Company Overview
9.1.2. Product Portfolio and Description
9.1.3. Financial Overview
9.1.4. Key Developments
9.2. Medtronic Plc
9.3. Abbott Laboratories
9.4. Novo Nordisk A/S
9.5. DexCom, Inc.
9.6. Nipro Medical
9.7. Sol-Millennium Medical Group
9.8. SABIC
9.9. Colexa Biosensor Ltd.
9.10. AMETEK.Inc. (*LIST NOT EXHAUSTIVE)
10. Appendix
10.1. About Us and Services
10.2. Contact Us